首页> 外文期刊>Cancer science. >Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast
【24h】

Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast

机译:Vasohibin-1作为乳腺导管癌侵袭行为的潜在预测指标

获取原文
获取原文并翻译 | 示例
           

摘要

Vasohibin-1 is a recently identified negative feedback regulator of angiogenesis induced by VEGF-A and bFGF. In this study, we first evaluated mRNA expression of vasohibin-1 and CD31 in 39 Japanese female breast carcinoma specimens including 22 invasive ductal carcinoma (IDC) and 17 ductal carcinoma in situ (DOS) using a real-time quantitative RT-PCR (QRT-PCR) with LightCycler system. In addition, we also immunolocalized vasohibin-1 and CD31 and compared their immunoreactivity to nuclear grades and histologi-cal grades of 100 carcinoma cases (50 IDC and 50 DCIS). There were no statistically significant differences of CD31 mRNA expression and the number of CD31 positive vessels between DCIS and IDC (P = 0.250 and P = 0.191, respectively), whereas there was a statistically significant difference in vasohibin-1 mRNA expression and the number of vasohibin-1 positive vessels in DCIS and IDC (P = 0.022 and P < 0.001, respectively). There was a significant positive correlation between vasohibin-1 mRNA level and Ki-67 labeling index in DCIS (r2 = 0.293, P < 0.001). In addition, vasohibin-1 mRNA expression was correlated with high nuclear and his-tological grades in DCIS cases and a significant positive correlation was detected between the number of vasohibin-1 positive vessels and Ki-67 labeling index or nuclear grade or Van Nuys classification of carcinoma cells (P < 0.001, respectively). These results all indicate the possible correlation between aggressive biological features in DCIS including increased tumor cell proliferation and the status of neovascularization determined by vasohibin-1 immunoreactivity.
机译:Vasohibin-1是最近发现的由VEGF-A和bFGF诱导的血管生成的负反馈调节剂。在这项研究中,我们首先使用实时定量RT-PCR(QRT)评估了39个日本女性乳腺癌标本中vasohibin-1和CD31的mRNA表达,其中包括22个浸润性导管癌(IDC)和17个原位导管癌(DOS)。 -PCR)与LightCycler系统。此外,我们还对vasohibin-1和CD31进行了免疫定位,并比较了它们与100例癌症病例(50例IDC和50例DCIS)的核级和组织学级的免疫反应性。 DCIS和IDC之间CD31 mRNA表达和CD31阳性血管数目无统计学差异(分别为P = 0.250和P = 0.191),而vasohibin-1 mRNA表达和CD31阳性血管数目有统计学差异。 DCIS和IDC中的vasohibin-1阳性血管(分别为P = 0.022和P <0.001)。 DCIS中血管抑制素-1 mRNA水平与Ki-67标记指数之间存在显着正相关(r2 = 0.293,P <0.001)。此外,DCIS患者中血管抑制素-1 mRNA的表达与高核和组织学分级相关,并且血管抑制素-1阳性血管的数量与Ki-67标记指数或核分级或Van Nuys分类之间呈显着正相关。癌细胞数(分别为P <0.001)。这些结果都表明,DCIS的侵袭性生物学特征(包括肿瘤细胞增殖增加)与由血管抑制素1免疫反应确定的新血管形成状态之间可能存在相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号